Analysis of the PI3K-AKT-mTOR pathway in penile cancer: evaluation of a therapeutically targetable pathway

Objectives To determine whether phosphatidylinositol-4,5-bisphosphate 3- kinase, catalytic subunit alpha (PIK3CA) copy number gain is common and could prove a useful marker for the activation status of the PI3K-AKT-mTOR pathway in penile squamous cell carcinoma (PSCC). Methods Fresh frozen tissue and archival blocks were collected from 24 PSCC patients with 15 matched normal penile epithelium (NPE) tissue from St George’s Hospital. PIK3CA mutational and copy number status (CNS) was assessed via Sanger sequencing and fluorescence in-situ hybridisation, respectively. PIK3CA RNA expression was quantified using TaqMan gene expression assay. HPV DNA was detected with INNO-LiPA assay. p-AKT and p-mTOR protein expression were assessed using western blot and immunohistochemistry. Results PIK3CA copy number gain was found in 11/23 (48%) patients, with mutations present in only 2/24 (8%) patients. In comparison to NPE, PSCC showed significantly lower PIK3CA RNA expression (p=0.0007), p-AKT (Ser473) nuclear immunoexpression (p=0.026) and protein expression of p-AKT (Thr308) (p=0.0247) and p-mTOR (Ser2448) (p=0.0041). No association was found between PIK3CA CNS and p-AKT and p-mTOR protein expression. Conclusion Based on our results the PI3K-AKT-mTOR pathway is not a key driver in PSCC carcinogenesis and the therapeutic targeting of this pathway is unlikely to produce significant clinical benefit.

[1]  L. Mariani,et al.  Panitumumab Treatment for Advanced Penile Squamous Cell Carcinoma When Surgery and Chemotherapy Have Failed. , 2016, Clinical genitourinary cancer.

[2]  D. Berney,et al.  DNA Copy Number Aberrations, and Human Papillomavirus Status in Penile Carcinoma. Clinico-Pathological Correlations and Potential Driver Genes , 2016, PloS one.

[3]  A. Vivancos,et al.  Identification of somatic gene mutations in penile squamous cell carcinoma , 2015, Genes, chromosomes & cancer.

[4]  A. Muneer,et al.  Epidemiology of penile cancer. , 2015, Current problems in cancer.

[5]  L. Mell,et al.  Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck. , 2015, Oral oncology.

[6]  Jean J. Zhao,et al.  PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting , 2014, Nature Reviews Cancer.

[7]  C. Scapulatempo-Neto,et al.  Genomic Profiling of Human Penile Carcinoma Predicts Worse Prognosis and Survival , 2014, Cancer Prevention Research.

[8]  H. Gómez,et al.  PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers. , 2014, Hematology/oncology and stem cell therapy.

[9]  T. Ecke,et al.  Metastatic penile carcinoma – an update on the current diagnosis and treatment options , 2014, Central European journal of urology.

[10]  C. Ng,et al.  Epidermal growth factor receptor‐targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis , 2014, BJU international.

[11]  J. Hicks,et al.  Immunohistochemical expression of the mammalian target of rapamycin pathway in penile squamous cell carcinomas: a tissue microarray study of 112 cases , 2014, Histopathology.

[12]  C. Porta,et al.  Targeting PI3K/Akt/mTOR Signaling in Cancer , 2014, Front. Oncol..

[13]  D. Berney,et al.  Identification of ZDHHC14 as a novel human tumour suppressor gene , 2014, The Journal of pathology.

[14]  S. Mojal,et al.  mTOR signaling pathway in penile squamous cell carcinoma: pmTOR and peIF4E over expression correlate with aggressive tumor behavior. , 2013, The Journal of urology.

[15]  P. Korkolopoulou,et al.  A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features. , 2013, Oncology reports.

[16]  A. Tinker,et al.  Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199). , 2013, Gynecologic oncology.

[17]  J. Lee,et al.  Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  G. Sonpavde,et al.  Penile cancer: current therapy and future directions. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  J. Testa,et al.  Diverse mechanisms of AKT pathway activation in human malignancy. , 2013, Current cancer drug targets.

[20]  P. Korkolopoulou,et al.  A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3‐kinase/v‐akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma , 2012, BJU international.

[21]  K. Mahajan,et al.  PI3K‐independent AKT activation in cancers: A treasure trove for novel therapeutics , 2012, Journal of cellular physiology.

[22]  R. Nigam,et al.  Conservative surgery for squamous cell carcinoma of the penis: resection margins and long-term oncological control. , 2012, The Journal of urology.

[23]  E. Marcotte,et al.  Insights into the regulation of protein abundance from proteomic and transcriptomic analyses , 2012, Nature Reviews Genetics.

[24]  S. Hewitt,et al.  mTOR as a Molecular Target in HPV-Associated Oral and Cervical Squamous Carcinomas , 2012, Clinical Cancer Research.

[25]  D. Culkin,et al.  Advanced penile cancer , 2012, International Urology and Nephrology.

[26]  M. Colecchia,et al.  Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  R. Rocha,et al.  Penile Cancer: Epidemiology and Treatment , 2011, Current oncology reports.

[28]  J. Cuzick,et al.  Alternative HER/PTEN/Akt Pathway Activation in HPV Positive and Negative Penile Carcinomas , 2011, PloS one.

[29]  S. Serrano,et al.  PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events , 2011, Modern Pathology.

[30]  X. Yao,et al.  Feasibility and Activity of Sorafenib and Sunitinib in Advanced Penile Cancer: A Preliminary Report , 2010, Urologia Internationalis.

[31]  Gang Chen,et al.  Activation of PI3K/Akt/IKK-α/NF-κB signaling pathway is required for the apoptosis-evasion in human salivary adenoid cystic carcinoma: its inhibition by quercetin , 2010, Apoptosis.

[32]  R. Memmott,et al.  Akt-dependent and -independent mechanisms of mTOR regulation in cancer. , 2009, Cellular signalling.

[33]  T. Ushijima,et al.  Overexpression of PIK3CA is associated with lymph node metastasis in esophageal squamous cell carcinoma. , 2009, International journal of oncology.

[34]  P. Söderkvist,et al.  PIK3CA, HRAS and KRAS gene mutations in human penile cancer. , 2008, The Journal of urology.

[35]  Robin Mathew,et al.  Role of autophagy in cancer , 2007, Nature Reviews Cancer.

[36]  C. Arens,et al.  Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma. , 2007, Oncology reports.

[37]  A. Goldberg,et al.  Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. , 2006, Journal of the American Society of Nephrology : JASN.

[38]  A. Molven,et al.  Molecular analysis of the PI3K‐AKT pathway in uterine cervical neoplasia: Frequent PIK3CA amplification and AKT phosphorylation , 2006, International journal of cancer.

[39]  H. Klocker,et al.  Genome-wide analysis of deoxyribonucleic acid in endometrial cancer using comparative genomic hybridization microarrays , 2005, International Journal of Gynecologic Cancer.

[40]  K. Loughlin.  What surgical resection margins are required to achieve oncological control in men with primary penile cancer? , 2006, BJU international.

[41]  Cristina M. Pinto,et al.  Retracted: Frequent genetic and biochemical alterations of the PI 3‐K/AKT/PTEN pathway in head and neck squamous cell carcinoma , 2005, International journal of cancer.

[42]  Chi Li,et al.  Growth Factor Regulation of Autophagy and Cell Survival in the Absence of Apoptosis , 2005, Cell.

[43]  Andrew K Godwin,et al.  AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth , 2004, Oncogene.

[44]  J. Blenis,et al.  Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression , 2004, Oncogene.

[45]  M. J. Fry,et al.  The phosphoinositide (PI) 3-kinase family , 2003, Journal of Cell Science.

[46]  V. Gabai,et al.  Necrosis: a specific form of programmed cell death? , 2003, Experimental cell research.

[47]  F. Algaba,et al.  EAU guidelines on penile cancer. , 2002, European urology.

[48]  R. Redon,et al.  A simple specific pattern of chromosomal aberrations at early stages of head and neck squamous cell carcinomas: PIK3CA but not p63 gene as a likely target of 3q26-qter gains. , 2001, Cancer research.

[49]  Chen-Yang Shen,et al.  PIK3CA as an oncogene in cervical cancer , 2000, Oncogene.

[50]  E. Compérat,et al.  EAU guidelines on penile cancer: 2014 update. , 2015, European urology.

[51]  V. Gabai,et al.  Mechanisms of tumor cell necrosis. , 2010, Current pharmaceutical design.